Meta-analysis of XXXX mutations and survival after resection of @entity14 .

@entity1 @entity3012 @entity984 @entity470 @entity14 @entity4434
BACKGROUND: In @entity1 with advanced @entity14 , @entity984 mutation status predicts response to treatment with monoclonal antibody targeting the @entity470 ( @entity470 ). Recent reports have provided evidence that @entity984 mutation status has prognostic value in @entity1 with resectable @entity14 ( @entity14 ) irrespective of treatment with chemotherapy or anti- @entity470 therapy. A meta-analysis was undertaken to clarify the impact of @entity984 mutation on outcomes in @entity1 with resectable @entity14 . METHODS: PubMed, Embase and Cochrane Library databases were searched systematically to identify full-text articles reporting @entity984 -stratified overall ( @entity3012 ) or recurrence-free ( @entity4434 ) survival after resection of @entity14 . Hazard ratios (HRs) and 95 per cent c.i. from multivariable analyses were pooled in meta-analyses, and a random-effects model was used to calculate weight and overall results. RESULTS: The search returned 355 articles, of which 14, including 1809 @entity1 , met the inclusion criteria. Eight studies reported @entity3012 after resection of @entity14 in 1181 @entity1 . The mutation rate was 27.6 per cent, and @entity984 mutation was negatively associated with @entity3012 (HR 2.24, 95 per cent c.i. 1.76 to 2.85). Seven studies reported @entity4434 after resection of @entity14 in 906 @entity1 . The mutation rate was 28.0 per cent, and @entity984 mutation was negatively associated with @entity4434 (HR 1.89, 1.54 to 2.32). CONCLUSION: @entity984 mutation status is a prognostic factor in @entity1 undergoing resection of @entity14 and should be considered in the evaluation of @entity1 having liver resection.
